Hematopoietic Stem Cell Transplantation (HSCT) in India
Get Hematopoietic Stem Cell Transplantation (HSCT) at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Hematopoietic Stem Cell Transplantation (HSCT) in UAE
Hematopoietic Stem Cell Transplantation (HSCT) at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Haematopoietic Stem Cell Transplantation (HSCT), commonly known as Bone Marrow Transplantation (BMT), is a life-saving procedure used to reconstitute a patient's haematopoietic system following high-dose chemotherapy or radiation, with allogeneic HSCT achieving long-term disease-free survival rates of 50–80% depending on disease type, donor compatibility, and patient fitness. India and the UAE have emerged as leading global destinations for HSCT, offering internationally accredited transplant centres staffed by haematologists trained at world-renowned institutions, at a fraction of the cost compared to the United States, United Kingdom, or Europe. GAF Healthcare connects international patients with top-tier NABH- and JCI-accredited BMT units in India and JCI- and DHA-licensed transplant programmes in Dubai and Abu Dhabi, managing every step from pre-transplant workup coordination to post-engraftment follow-up and safe repatriation.
Hospital Stay: 30–60 days (inpatient; varies by transplant type — autologous typically 21–35 days, allogeneic 40–60 days) • Total Stay in Country (Fit-to-Fly): 10–16 weeks from transplant day (fit-to-fly clearance requires stable engraftment, absence of active GVHD, ANC ≥ 0.5 × 10⁹/L sustained, and infectious disease clearance by the treating haematologist) • Success Rate: 50–80% long-term disease-free survival (disease- and donor-dependent; autologous HSCT for multiple myeloma: 70–85%; matched sibling allogeneic HSCT for AML in CR1: 55–70%)
What Is It?
Haematopoietic Stem Cell Transplantation (HSCT) is the infusion of pluripotent haematopoietic progenitor cells — sourced from bone marrow, peripheral blood, or umbilical cord blood — into a conditioned recipient with the goal of restoring normal haematopoiesis and, in allogeneic settings, inducing a graft-versus-tumour (GVT) immune effect. The procedure is broadly classified as autologous (patient's own stem cells re-infused after myeloablative chemotherapy) or allogeneic (donor cells from a matched sibling, matched unrelated donor, haploidentical relative, or cord blood unit). The physiological impact is profound: conditioning regimens such as BuCy (busulfan + cyclophosphamide), FluBu (fludarabine + busulfan), or TBI-based protocols ablate the recipient's marrow, rendering them profoundly immunosuppressed and pancytopenic for 2–6 weeks before donor engraftment restores marrow function.
The spectrum of diseases treated by HSCT is wide and includes haematological malignancies (acute myeloid leukaemia, acute lymphoblastic leukaemia, chronic myeloid leukaemia, myelodysplastic syndromes, lymphomas, and multiple myeloma), non-malignant conditions (aplastic anaemia, thalassaemia major, sickle cell disease, Fanconi anaemia, SCID, and inherited metabolic disorders), and, increasingly, autoimmune diseases under HSCT-for-autoimmunity protocols. The EBMT and CIBMTR risk scores — including the HCT-CI (Haematopoietic Cell Transplantation Comorbidity Index) and the Disease Risk Index (DRI) — guide patient selection and prognostication. Modern prophylaxis regimens targeting graft-versus-host disease (GVHD) have advanced significantly, with calcineurin inhibitor combinations, post-transplant cyclophosphamide (PTCy), and JAK1/2 inhibitors such as ruxolitinib now standard of care in many centres.
The current standard of care in high-volume Indian and UAE transplant centres mirrors international EBMT and ASBMT guidelines. Conditioning intensity is tailored to patient age, comorbidity burden (HCT-CI), and disease risk: myeloablative conditioning (MAC) for younger, fit patients, and reduced-intensity conditioning (RIC) or non-myeloablative conditioning (NMA) for older or comorbid patients. GVHD prophylaxis platforms have evolved from classical cyclosporine + methotrexate to tacrolimus + sirolimus, PTCy-based haploidentical protocols (Baltimore protocol), and CD34+ positive selection for T-cell depletion. Infection surveillance with galactomannan, beta-D-glucan, CMV/EBV PCR monitoring, and antifungal prophylaxis with posaconazole or voriconazole are standard. State-of-the-art HEPA-filtered laminar airflow rooms, dedicated BMT pharmacists, and 24/7 blood bank support with irradiated and CMV-negative blood products are routinely available at GAF Healthcare's partner hospitals.
Candidates
• ELIGIBLE CONDITIONS (Malignant): Acute Myeloid Leukaemia (AML) in CR1/CR2, Acute Lymphoblastic Leukaemia (ALL) in CR1 (high-risk) or CR2, Chronic Myeloid Leukaemia (CML) in accelerated/blast phase or TKI-refractory, Myelodysplastic Syndromes (MDS) with IPSS-R intermediate or higher, Hodgkin and Non-Hodgkin Lymphoma (relapsed/refractory or high-risk), Multiple Myeloma (autologous HSCT as consolidation post-induction), Myelofibrosis (allogeneic HSCT for DIPSS+ intermediate-2 or high risk)
• ELIGIBLE CONDITIONS (Non-Malignant): Severe Aplastic Anaemia (SAA), Thalassaemia Major (Lucarelli Class I–III), Sickle Cell Disease with major organ complications, SCID and primary immunodeficiencies, Fanconi Anaemia, Wiskott-Aldrich Syndrome, Hurler Syndrome and selected lysosomal storage disorders, POEMS syndrome
• ELIGIBLE CONDITIONS (Autoimmune — Investigational/Specialist Centres): Refractory Multiple Sclerosis (MS), Systemic Sclerosis, Crohn's Disease (autologous HSCT under EBMT guidelines)
• REQUIRED PRE-TRANSPLANT DIAGNOSTICS: Bone marrow biopsy and trephine with cytogenetics (karyotype, FISH), molecular profiling (NGS panel for FLT3, NPM1, IDH1/2, TP53, ASXL1), HLA typing (high-resolution 10/10 allele-level for patient and donor), PET-CT scan (for lymphoma patients to confirm complete remission pre-transplant), ECHO (left ventricular ejection fraction must typically be ≥ 45%), Pulmonary Function Tests (DLCO ≥ 50% predicted), Creatinine clearance (GFR ≥ 40–60 mL/min depending on regimen), Liver function and bilirubin (Child-Pugh scoring), CMV/EBV/HSV/VZV/HBV/HCV/HIV serology for patient and donor, HCT-CI comorbidity scoring, Dental clearance and ENT evaluation, Fertility counselling and sperm/oocyte cryopreservation discussion
• CONTRAINDICATIONS (Absolute or Relative): LVEF < 40% or uncontrolled cardiac failure, Severe hepatic dysfunction (bilirubin > 3× ULN, cirrhosis), Active uncontrolled systemic infection at time of conditioning, Active solid organ malignancy (other than indication), ECOG performance status ≥ 3 for myeloablative regimens (RIC may be considered in selected patients), Active psychiatric illness precluding informed consent or treatment compliance, Lack of suitable donor (for allogeneic) — though haploidentical and cord blood programmes have significantly reduced this barrier
Procedure
AUTOLOGOUS HSCT (Auto-SCT):
In autologous HSCT, the patient's own peripheral blood stem cells (PBSCs) are mobilised using G-CSF (filgrastim or plerixafor + G-CSF for poor mobilisers), collected by large-volume leukapheresis (targeting ≥ 2–4 × 10⁶ CD34+ cells/kg), cryopreserved in DMSO, and re-infused after high-dose chemotherapy conditioning. Standard conditioning regimens include BEAM (carmustine, etoposide, cytarabine, melphalan) for lymphomas and Melphalan 200 mg/m² (Mel200) for multiple myeloma. Auto-HSCT carries no GVHD risk and has faster immune reconstitution but no GVT effect, carrying a higher relapse risk for AML. Tandem autologous transplants (two sequential auto-HSCTs) are used in high-risk myeloma at specialist centres.
ALLOGENEIC HSCT (Allo-SCT) — MATCHED SIBLING DONOR (MSD):
MSD allo-HSCT remains the gold standard for most haematological malignancies. The donor undergoes G-CSF mobilisation (peripheral blood stem cell collection is now preferred over surgical bone marrow harvest in most adult programmes due to faster engraftment). The graft contains T-cells that mediate GVT effect. GVHD prophylaxis typically uses tacrolimus + methotrexate (short course) or tacrolimus + sirolimus. Myeloablative conditioning (BuCy4, TBI 12 Gy + cyclophosphamide) is standard for fit patients < 55 years. RIC (FluBu2 or Flu-Mel) is used for older or comorbid patients.
ALLOGENEIC HSCT — MATCHED UNRELATED DONOR (MUD):
For patients lacking an MSD, a 10/10 or 9/10 HLA-matched unrelated donor is identified via the NMDP, DKMS, or national registries. MUD transplants carry higher GVHD risk than MSD, requiring more intensive GVHD prophylaxis. ATG (anti-thymocyte globulin) is commonly added to prophylaxis. India and UAE centres with active registry access can facilitate MUD transplants with international donor sourcing, typically adding 6–12 weeks to donor identification timelines.
HAPLOIDENTICAL HSCT (Haplo-SCT) — BALTIMORE PROTOCOL:
Haploidentical transplantation (50% HLA-matched parent, sibling, or child) using post-transplant cyclophosphamide (PTCy on days +3 and +4) has transformed access to allogeneic HSCT. Nearly every patient has a haploidentical donor available. Baltimore protocol (PTCy + tacrolimus + MMF) has made haplo-HSCT outcomes comparable to MUD in many disease settings. This is increasingly the preferred option in India for patients without MSD and in centres with limited MUD registry access.
UMBILICAL CORD BLOOD TRANSPLANTATION (UCBT):
Cord blood units offer HLA flexibility (4–6/6 matching acceptable), reduced GVHD despite HLA mismatch, and immediate availability. The main limitation is cell dose (weight ≥ 40 kg patients may require double cord blood units). Cord blood transplantation is preferred in paediatric patients lacking other donor options and in some ethnic minorities with limited MUD registry representation.
NON-MYELOABLATIVE / MINI-TRANSPLANTS:
For elderly patients (> 60–65 years) or those with significant comorbidities (HCT-CI ≥ 3), non-myeloablative or reduced-intensity conditioning regimens (fludarabine-based: Flu-TBI 2 Gy, FluBu2) allow allogeneic engraftment while relying on GVT rather than cytotoxic ablation for disease control. These carry lower early treatment-related mortality but require intact residual marrow for engraftment.
ADVANCED TECHNOLOGIES AT PARTNER CENTRES:
• CD34+ positive selection / T-cell depletion using CliniMACS (Miltenyi Biotec) for haploidentical or high-risk GVHD scenarios
• Next-generation sequencing (NGS) measurable residual disease (MRD) monitoring post-transplant to guide pre-emptive intervention
• Donor lymphocyte infusion (DLI) for relapse management post-allo-HSCT
• CAR-T cell therapy (Chimeric Antigen Receptor T-cell) as bridging or salvage in relapsed/refractory ALL and DLBCL prior to or post-HSCT at select partner centres in India
• Ruxolitinib (JAK1/2 inhibitor) for steroid-refractory acute GVHD (FDA/EMA approved; available at partner centres)
• Vedolizumab and belumosudil for chronic GVHD management
• Prophylactic letermovir for CMV prevention in CMV-seropositive allo-HSCT recipients
Cost of Hematopoietic Stem Cell Transplantation (HSCT): India vs. UAE
HSCT is one of the most resource-intensive procedures in modern medicine, and the destination of treatment significantly impacts total expenditure. India offers world-class BMT programmes at costs that are 50–65% lower than equivalent centres in the UAE and 70–80% lower than the United States or United Kingdom, without compromising on accreditation standards, conditioning drug availability, or transplant expertise. UAE centres — particularly in Dubai and Abu Dhabi — offer premium infrastructure, luxury patient accommodation, and seamless connectivity for patients from the Gulf region, East Africa, and Europe. The cost ranges below reflect the total in-hospital package for the transplant episode and do not include pre-transplant diagnostics, international donor sourcing fees (for MUD transplants), medications dispensed after discharge, or long-term follow-up. Autologous HSCT sits at the lower end of these ranges; myeloablative matched unrelated donor allogeneic HSCT at the higher end. GAF Healthcare provides a personalised, itemised cost estimate for each patient following case review.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $18,000 – $45,000 | ~59% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $45,000 – $110,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — INITIAL ASSESSMENT & GAF HEALTHCARE CASE REVIEW (Weeks -12 to -8 before transplant):
• Patient submits medical records to GAF Healthcare (bone marrow biopsy reports, molecular panels, HLA typing, imaging, echocardiogram, PFTs, complete blood count, metabolic panel)
• GAF Healthcare's medical team conducts a structured case review and presents the case to shortlisted transplant centres in India or UAE
• Written transplant plan (conditioning regimen, donor strategy, estimated timeline, cost estimate) received from the centre within 5–7 business days
• e-Medical Visa (India) or UAE entry visa application initiated with GAF Healthcare's immigration support team
PHASE 2 — PRE-TRANSPLANT WORKUP IN COUNTRY (Days -30 to -14):
• Patient and attendant arrive in country; GAF Healthcare provides airport pickup and hospital check-in facilitation
• Comprehensive inpatient pre-transplant evaluation: repeat bone marrow biopsy (confirm remission status), PET-CT (lymphoma cases), ECHO, PFTs, renal function, liver biopsy if indicated, infectious disease serology, dental review, dermatology (chronic skin conditions), ophthalmology (if prior TBI)
• HCT-CI scoring finalised; conditioning regimen and GVHD prophylaxis platform confirmed by transplant team
• Donor workup completed (for allogeneic HSCT): donor medical history, infectious serology, HLA confirmatory testing, donation counselling
• Fertility preservation (sperm cryopreservation or oocyte cryopreservation) offered and arranged if indicated
• Tunnelled central venous catheter (Hickman line or PICC) placed under ultrasound guidance
• Patient admitted to dedicated HEPA-filtered, laminar airflow, positive-pressure BMT isolation room
PHASE 3 — CONDITIONING REGIMEN (Days -7 to -1):
• High-dose chemotherapy and/or Total Body Irradiation (TBI) administered over 5–7 days according to planned protocol (e.g., BuCy4: busulfan days -7 to -4, cyclophosphamide days -3 to -2; BEAM: days -6 to -1)
• Busulfan levels monitored with pharmacokinetic (PK) sampling on Day -7 to enable individualised dose adjustment (AUC targeting 900–1350 µmol·min/L) — reducing both hepatic veno-occlusive disease (VOD) risk and graft failure risk
• Ursodeoxycholic acid and IV hydration for VOD prophylaxis; anti-emetics, mucositis prophylaxis (ice chips/cryotherapy during melphalan infusion, oral decontamination with chlorhexidine)
• Antimicrobial prophylaxis initiated: aciclovir (HSV/VZV), fluconazole or posaconazole (fungal), co-trimoxazole (Pneumocystis jirovecii)
PHASE 4 — TRANSPLANT DAY (Day 0):
• Stem cell infusion administered via central venous catheter (analogous to a blood transfusion in appearance)
• Premedication with hydrocortisone and chlorphenamine to reduce DMSO-related reactions (autologous) or infusion reactions (allogeneic)
• Continuous vital sign monitoring throughout infusion; infusion typically takes 30 minutes to 4 hours depending on graft volume
• For haploidentical transplants: G-CSF–mobilised PBSC graft infused on Day 0; PTCy administered on Days +3 and +4
PHASE 5 — ENGRAFTMENT PHASE (Days +1 to +28):
• Patient remains in isolation; daily full blood counts to monitor neutrophil and platelet recovery
• Typical neutrophil engraftment (ANC ≥ 0.5 × 10⁹/L × 3 consecutive days): Day +10 to +18 (autologous) or Day +14 to +28 (allogeneic)
• Platelet transfusion threshold maintained (typically ≥ 10 × 10⁹/L or ≥ 20 × 10⁹/L if febrile)
• CMV/EBV PCR monitoring twice weekly in allogeneic recipients; pre-emptive ganciclovir or foscarnet for CMV reactivation
• Febrile neutropenia managed with broad-spectrum IV antibiotics (piperacillin-tazobactam or meropenem as per local antibiogram); CT thorax if suspected invasive fungal infection (galactomannan-guided)
• GVHD surveillance: daily skin, GI (stool frequency/character), and liver (bilirubin) assessment; GVHD grading by Modified Glucksberg criteria
• Tacrolimus/sirolimus levels monitored every 2–3 days with dose adjustment
PHASE 6 — EARLY POST-ENGRAFTMENT RECOVERY (Days +28 to +60):
• Patient transitions from isolation room to general BMT ward once ANC sustained ≥ 0.5 × 10⁹/L and afebrile
• Bone marrow chimerism testing (STR-PCR) at Day +30 and +60 to confirm full donor engraftment
• MRD assessment by NGS or flow cytometry to evaluate remission depth
• Oral medications transitioned; Hickman line removed when peripheral access adequate
• Nutritional rehabilitation with dietitian support; physiotherapy to address deconditioning
• Outpatient day-care visits begin (3× weekly reducing to weekly) for blood count monitoring, tacrolimus levels, and clinical GVHD assessment
• Patient and attendant accommodated in hospital guesthouse or GAF Healthcare partner serviced apartment
PHASE 7 — FIT-TO-FLY CLEARANCE & DEPARTURE PLANNING (Weeks 10–16 post-transplant):
• Fit-to-fly criteria assessed: stable engraftment with ANC > 1.0 × 10⁹/L, platelets > 50 × 10⁹/L, no active GVHD Grade ≥ 2, no active infection, ECOG PS ≤ 2, no oxygen requirement
• Comprehensive discharge summary, outpatient immunosuppression plan, infection prophylaxis schedule, vaccination roadmap (live vaccines deferred 12–24 months post-transplant), and emergency contact protocol prepared by transplant team
• GAF Healthcare coordinates medical escort if required for long-haul repatriation
• Long-term follow-up: patients continue immunosuppression (typically 6–12 months for allogeneic HSCT), annual bone marrow assessments, and chimerism/MRD monitoring at home country with coordination via GAF Healthcare's telemedicine team
Risks & Considerations
HSCT carries significant treatment-related morbidity and mortality that every patient and family must understand prior to proceeding. The overall treatment-related mortality (TRM) at 100 days ranges from 2–5% for autologous HSCT in fit patients to 10–25% for myeloablative allogeneic HSCT in high-risk or older patients, largely driven by infection, organ toxicity, and GVHD.
Key procedural and post-procedural risks include:
Top Hospitals for Hematopoietic Stem Cell Transplantation (HSCT)
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Tata Memorial Hospital
Mumbai, India
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Top Doctors for Hematopoietic Stem Cell Transplantation (HSCT)
Internationally trained specialists in Hematology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Rahul Bhargava
MBBS, MD (General Medicine), DM (Clinical Hematology), Advanced Fellowship in Unrelated and Haploidentical Transplant
Hematologist & BMT Specialist
Fortis Memorial Research Institute, Gurgaon, India
20+ Yearsof experience
Dr. Rahul Bhargava is a leading Hematologist and BMT specialist currently working at Fortis Memorial Research Institute, Gurugram. With an experience of more than 20 years in Hematology, Pediatric Hemato-Oncology, and Bone Marrow Transplantation, he has performed numerous BMTs with consistently successful outcomes and is widely regarded as one of the most trusted names in this highly specialised field in India. He primarily specialises in haploidentical… Read more
Dr. Vikas Dua
MBBS, MD (Paediatrics), FNB (Paediatric Hematology Oncology), Fellowship in Paediatric Bone Marrow Transplant, Outreach Programme in Paediatric BMT
Pediatric Hematologist & BMT Specialist
Fortis Memorial Research Institute, Gurgaon, India
20+ Yearsof experience
Dr. Vikas Dua is one of the leading paediatric hemato-oncologists and bone marrow transplant specialists of his generation. He currently serves as Principal Director & Head — Paediatric Haematology, Haemato-Oncology and Bone Marrow Transplant at Fortis Memorial Research Institute, Gurgaon. Dr. Dua and his team have performed more than 1,200 transplants, with outcomes among the best in the field of paediatric haematology, oncology and BMT. He is… Read more
Dr. Amita Mahajan
MBBS, MD (Pediatrics), MRCPCH, CCST (Advanced Training in Pediatric Oncology)
Pediatric Hematologist and Oncologist
Indraprastha Apollo Hospital, New Delhi, India
32+ Yearsof experience
Dr. Amita Mahajan is a Senior Consultant in Pediatric Hematology and Oncology at Indraprastha Apollo Hospital, New Delhi, with over 32 years of dedicated clinical experience in childhood blood disorders and cancers. She completed her MBBS and MD in Pediatrics from the All India Institute of Medical Sciences (AIIMS), New Delhi, followed by advanced international training: the MRCPCH from the Royal College of Paediatrics and Child Health, London, and… Read more
Dr. Govind Eriat
MBBS, DNB, FRCP, Fellowship in Leukemia/BMT
Hematologist & Hemato-Oncologist
Gleneagles Hospitals, Bengaluru, India
14+ Yearsof experience
Dr. Govind Eriat is a Visiting Consultant in Hematology and Hemato-Oncology at Gleneagles Hospitals, Bengaluru, bringing over 14 years of specialized clinical experience in blood disorders and cancer care. He holds an MBBS degree and has completed his DNB in Internal Medicine, establishing a strong foundation in comprehensive patient care. His international credentials include Fellowship from the Royal College of Physicians (FRCP), United Kingdom, and a… Read more
Dr. K. Karuna Kumar
MD, DNB Clinical Hematology
Hematologist
Yashoda Hospitals, Secunderabad, Hyderabad, India
18+ Yearsof experience
Dr. K. Karuna Kumar is a Clinical Consultant in Hematology with over 18 years of specialised clinical experience. He holds an MD from Nizam's Institute of Medical Sciences (NIMS), Hyderabad, and a DNB in Clinical Hematology from Narayana Hrudayalaya, Bangalore—two of India's most prestigious medical institutions. His training has equipped him with exceptional expertise in both benign and malignant blood disorders, as well as complex transplant procedures.… Read more
Frequently Asked Questions — Hematopoietic Stem Cell Transplantation (HSCT)
The total in-hospital cost of HSCT varies significantly based on the transplant type (autologous vs. allogeneic), donor source (matched sibling, matched unrelated, or haploidentical), conditioning regimen intensity, length of inpatient stay, and any complications requiring additional intervention. In India, autologous HSCT (e.g., for multiple myeloma or lymphoma) typically costs between USD 18,000 and USD 28,000 inclusive of conditioning chemotherapy, stem cell collection and cryopreservation, the transplant admission (21–35 days), supportive medications, blood products, and standard monitoring. Allogeneic HSCT — matched sibling, MUD, or haploidentical — costs between USD 28,000 and USD 45,000, with higher costs driven by longer inpatient stays (40–60 days), GVHD prophylaxis drugs (tacrolimus, sirolimus, ATG), and intensive infection surveillance. These costs reflect care at NABH- and JCI-accredited centres in cities such as Mumbai, Delhi, Bengaluru, Chennai, and Hyderabad, which collectively perform among the highest volumes of HSCT in Asia. In the UAE (Dubai and Abu Dhabi), the same procedures are priced at USD 45,000–65,000 for autologous HSCT and USD 70,000–110,000 for allogeneic HSCT. UAE centres offer premium single-room accommodation, internationally trained nursing staff with lower nurse-to-patient ratios, and luxury patient services, along with JCI accreditation and DHA/DOH regulatory oversight. These costs are still 60–75% below equivalent procedures in the United States (where allo-HSCT routinely exceeds USD 300,000–500,000) or the United Kingdom. Neither range includes international matched unrelated donor (MUD) search and procurement fees (typically USD 5,000–20,000 depending on the registry and urgency), pre-transplant diagnostics conducted abroad, post-discharge outpatient medications, or return flights and accommodation. GAF Healthcare provides a fully itemised, personalised cost estimate within 5–7 business days of receiving complete medical records.
HSCT requires one of the longest mandatory in-country stays of any medical procedure, and patients and families must plan accordingly. The minimum in-country duration before fit-to-fly clearance is 10–16 weeks from the day of stem cell infusion (Day 0), though the median for allogeneic HSCT patients is 12–14 weeks. The hospital inpatient admission itself lasts 21–35 days for autologous HSCT and 40–60 days for allogeneic HSCT (longer if complications such as GVHD, CMV reactivation, or prolonged engraftment occur). Following discharge from the inpatient unit, patients are not fit to fly and must remain near the transplant centre for outpatient monitoring. During this phase, patients are seen 3–5 times per week (reducing to weekly as recovery progresses) for blood counts, drug level monitoring, GVHD assessment, and infectious surveillance. Formal fit-to-fly clearance is issued by the transplant physician when ALL of the following criteria are met: - Absolute Neutrophil Count (ANC) sustainably above 1.0 × 10⁹/L without G-CSF support - Platelet count ≥ 50 × 10⁹/L (or ≥ 80 × 10⁹/L for long-haul flights > 8 hours, at many centres) - No active GVHD Grade II or above requiring escalation of therapy - No active systemic infection (bacterial, fungal, or viral) - Stable oral immunosuppression with documented therapeutic drug levels - ECOG Performance Status ≤ 2 (patient can perform basic self-care and ambulate) - No supplemental oxygen requirement For allogeneic HSCT patients, fit-to-fly is rarely achievable before Week 10 post-transplant, and the majority are cleared between Weeks 12 and 16. Autologous HSCT patients may occasionally achieve fit-to-fly clearance as early as Week 6–8, but Week 8–12 is more typical. These timelines can be extended by complications. GAF Healthcare's Case Manager works with the transplant team to coordinate fit-to-fly certification, arrange medical escort if required, and liaise with airlines regarding oxygen requirements, preboarding, and infection precautions during travel.
The success rate of HSCT is not a single number — it is disease-specific, risk-stratified, and dependent on multiple patient, disease, and transplant-related factors. Published outcomes from EBMT (European Bone Marrow Transplantation Registry), CIBMTR (Center for International Blood and Marrow Transplant Research), and individual high-volume centres provide the most reliable benchmark data. KEY OUTCOME BENCHMARKS BY DISEASE AND TRANSPLANT TYPE: - Autologous HSCT for Multiple Myeloma (MM): 5-year progression-free survival (PFS) of 40–55% with modern induction (VRd or Dara-VRd) plus autologous transplant and lenalidomide maintenance; overall survival (OS) exceeds 70–80% at 5 years with tandem auto approach in high-risk disease. - Autologous HSCT for Hodgkin Lymphoma (relapsed/refractory, chemosensitive): 5-year OS of 50–60%; when combined with brentuximab vedotin consolidation post-transplant, 5-year PFS improves to approximately 65%. - Allogeneic HSCT for AML in First Complete Remission (CR1), standard-risk: 5-year disease-free survival (DFS) of 55–70% with matched sibling donor; 50–65% with MUD; approximately 45–60% with haploidentical (PTCy protocol). - Allogeneic HSCT for ALL in CR1 (high-risk, Ph+ or MRD-positive): 5-year DFS of 50–65% with MSD; outcomes are strongly influenced by MRD negativity at transplant. - Allogeneic HSCT for Severe Aplastic Anaemia (SAA) with MSD in patients < 40 years: 5-year OS exceeding 85–90%, making it potentially curative in the majority. - Allogeneic HSCT for Thalassaemia Major (Lucarelli Class I): event-free survival (EFS) of 85–93% in paediatric patients with MSD and good pre-transplant hepatic status. - Allogeneic HSCT for MDS (IPSS-R High/Very High): 3-year OS of 35–50%, heavily dependent on cytogenetic risk and MRD status at transplant. CRITICAL PROGNOSTIC FACTORS: The Disease Risk Index (DRI) — low, intermediate, high, and very high — is the most validated risk stratification tool and correlates strongly with post-HSCT survival. Low-DRI patients achieve 3-year OS > 65%; very-high-DRI patients < 30%. The HCT-CI (Haematopoietic Cell Transplantation Comorbidity Index) predicts treatment-related mortality independent of disease. KPS/ECOG performance status, CMV serostatus, MRD negativity at transplant, and donor-recipient sex mismatch also independently influence outcomes. GAF Healthcare's partner centres in India and the UAE report outcomes that are broadly consistent with published EBMT and CIBMTR registry data, reflecting their volume, experience, and protocol adherence. During the case review process, GAF Healthcare will share the transplant centre's disease-specific outcome data and help patients and families interpret the individualised risk-benefit assessment provided by the treating haematologist.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical support for international HSCT patients and their attendants, ensuring that logistical complexity never becomes a barrier to accessing life-saving treatment.
VISA & IMMIGRATION SUPPORT: For India: GAF Healthcare's visa team initiates and manages the e-Medical Visa (eMV) application on behalf of the patient and up to two attendants. The eMV is a triple-entry visa valid for 60 days per visit and can be extended to 180 days at the Foreigners Regional Registration Office (FRRO) — critical given HSCT's prolonged in-country stay requirements. A medical invitation letter from the partner hospital, certified by GAF Healthcare, is provided for the visa application. Patients from UAE, Saudi Arabia, Oman, Kuwait, Qatar, Bahrain, Egypt, Nigeria, Kenya, Tanzania, Bangladesh, and most countries outside Pakistan and Afghanistan qualify for e-Medical Visa. For UAE: Patients from over 50 countries (GCC nationals, US, UK, EU, Australia, many Asian nations) receive visa-on-arrival or visa-free access to the UAE. For other nationalities, GAF Healthcare coordinates a medical visit visa through the UAE hospital's Ministry of Health-approved patient visa pathway. DHA (Dubai Health Authority) and DOH (Abu Dhabi Department of Health) facilitate medical visitor documentation.
AIRPORT & IN-COUNTRY TRANSFERS: Private, infection-controlled vehicle transfers from international airport to hospital and between hospital and accommodation are arranged for all HSCT patients. HSCT patients are immunocompromised and cannot use shared transport; GAF Healthcare uses dedicated vehicles with HEPA-filtered air systems at select partner hospitals upon request. Wheelchair-accessible vehicles are available.
ACCOMMODATION FOR ATTENDANTS: HSCT requires a 2.5–4 month in-country stay. GAF Healthcare arranges furnished serviced apartments or hospital guest houses within 1–5 km of the transplant centre for the patient's family attendant(s), with weekly housekeeping, laundry, and basic kitchen facilities. Meal delivery services catering to dietary requirements (halal, vegetarian, allergen-specific) are coordinated. Accommodation options span budget to premium and are itemised transparently in the GAF Healthcare cost estimate.
DEDICATED CASE MANAGER & TRANSLATION SERVICES: Each HSCT patient is assigned a personal GAF Healthcare Case Manager who serves as the single point of contact between the family, the transplant team, and GAF Healthcare's operations team — available 7 days a week. Professional certified medical interpreters are available in Arabic, French, Russian, Swahili, Amharic, Bengali, Tagalog, Bahasa Indonesia, and other languages for clinical consultations, consent discussions, and discharge planning. Remote interpreter services are available via video for less common languages.
TELEMEDICINE & POST-DEPARTURE FOLLOW-UP: After safe repatriation, GAF Healthcare facilitates structured telemedicine follow-up consultations with the transplant team at the treating centre, enabling home-country physicians to co-manage immunosuppression tapering, GVHD surveillance, and MRD monitoring in coordination with international specialist oversight. Repeat bone marrow biopsy samples can be coordinated for courier to the transplant centre's molecular lab for MRD analysis where local expertise is unavailable.
Patients Also Explore
Other treatments commonly sought by patients considering Hematopoietic Stem Cell Transplantation (HSCT).
Breast Cancer Treatment
Cancer Care
Lung Cancer Treatment
Cancer Care
Liver Transplant
Transplant
Lung Transplant
Transplant